AI in Drug Discovery Xchange – San Francisco 2024
The AI in Drug Discovery Xchange in San Francisco, delivered by hubXchange, brings together executives from pharma and biotech to address and find solutions to the key issues faced in AI Drug Discovery.
Digital Science are delighted to be sponsoring this year’s event, and will be presenting the opening keynote, as well as a roundtable in the Data Quality track.
Opening Address & Keynote Presentation: The Future of AI in Pharma: Accelerating Research Workflows with GenAI
08:30 – 09:00, 26 Sept 2024
In this keynote presentation, we will explore the transformative impact of Generative AI (GenAI) on research workflows and systematic literature reviews within the pharmaceutical industry. Traditional AI technologies like natural language processing and machine learning have long been used to streamline screening and data synthesis. Recent advances in Generative AI and multimodal capabilities offer new opportunities to accelerate workflows at every stage. But despite the promise of GenAI, the human perspective remains crucial. We will discuss the evolving roles of researchers and the need to balance automation with human insight. Attendees will learn about the latest GenAI-driven tools, their integration into current workflows, and the ethical considerations involved. Join us to discover how AI enhances research processes by augmenting human expertise, driving innovation, and advancing progress in pharma.
Robert McGrath
Co-founder and CEO of ReadCube (Digital Science)
Robert McGrath
Co-founder and CEO of ReadCube (Digital Science)
ReadCube is a leader in scalable literature workflow solutions enhancing research driven teams by transforming the way scholarly literature is accessed, analyzed, monitored and interpreted. ReadCube’s adaptive suite of solutions, including the Papers reference manager, have helped millions of individuals and thousands of organizations globally. As a Digital Science solution, an AI-focused technology company providing innovative solutions to complex challenges, ReadCube works in partnership to advance global research for the benefit of society.
Before joining Digital Science, Robert worked on various software engineering projects at Microsoft, Franklin Templeton Investments, and early-stage software startups. He earned a degree in Computer Science from Harvard University.
Roundtable: How can we bring fact-based knowledge and language together in AI applications for drug discovery?
11:20 – 12:20, 26 Sept 2024
- What are the primary challenges and benefits of implementing generative AI in drug discovery processes?
- What are some current measures to ensure a trustworthy data layer for AI applications?
- What are the most promising applications of Generative AI for expediting the process and accuracy of drug discovery?
- What are the risks of AI-driven applications for the pharma space, such as ensuring results are compliant with legal and regulatory requirements?
- Previous experiments with methods such as RAG, NL2SPARQL, graph embeddings and, what the results have been?
Dr Peter Doerr
Director Presales – Solution Architecture and Strategy, metaphacts
Dr Peter Doerr
Director Presales – Solution Architecture and Strategy, metaphacts
Peter Doerr is leading the presales team at metaphacts, a subsidiary of Digital Science specialized on Knowledge Graphs. After completing his PhD in mathematics, his career took him through IT and telecommunications where he worked in senior commercial roles as Vice President for Telefonica and Huawei before returning to a science-driven environment. At Digital Science, as VP corporate solutions, he worked closely with the largest customers to align applications and customer needs.